文献速递卫生政策与健康促进传染病防控与疫情报告

2000-2017年G20国家1050亿美元传染病研究资金分配的内容分析

The allocation of USdollar;105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investments.
PubMed 文献 · Lancet Glob Health · 2020-01-01

BACKGROUND: Each year, billions of US$ are spent globally on infectious disease research and development. However, there is little systematic tracking of global research and development.…

要点

  • 梅毒和疥疮相对DALY投资最低(均为9美元/DALY)。
  • 埃博拉、寨卡、冠状病毒等投资多在疫情后反应性增加。

核心结论

  • HIV研究获得相对DALY负担最高的投资,疥疮和梅毒相对资金最低。
  • 高威胁病原体(如埃博拉病毒和冠状病毒)的投资常为反应性并跟随疫情。
  • 很少证据表明资金主动受全球疾病负担或大流行风险引导。

研究设计与样本

  • 研究考察2000-2017年G20国家公共与慈善资助方对传染病研究的资助。
  • 使用关键词检索研究数据库并从资助方网站提取开放获取数据。

关键数值与推荐

  • HIV/AIDS每DALY相对投资772美元,结核病156美元,疟疾125美元,肺炎33美元。
  • 梅毒和疥疮每DALY相对投资最低,均为9美元。

临床怎么用

  • 提示传染病研究资金分配与疾病负担存在弱关联,需关注低资助领域。
  • 高威胁病原体投资常滞后于疫情,应加强前瞻性资金规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Each year, billions of US$ are spent globally on infectious disease research and development. However, there is little systematic tracking of global research and development. We present research on investments into infectious diseases research from funders in the G20 countries across an 18-year time period spanning 2000-17, comparing amounts invested for different conditions and considering the global burden of disease to identify potential areas of relative underfunding. METHODS: The study examined research awards made between 2000 and 2017 for infectious disease research from G20-based public and philanthropic funders. We searched research databases using a range of keywords, and open access data were extracted from funder websites. Awards were categorised by type of science, specialty, and disease or pathogen. Data collected included study title, abstract, award amount, funder, and year. We used descriptive statistics and Spearman's correlation coefficient to investigate the association between research investment and disease burden, using Global Burden of Disease 2017 study data. FINDINGS: The final 2000-17 dataset included 94 074 awards for infectious disease research, with a sum investment of $104·9 billion (annual range 4·1 billion to 8·4 billion) and a median award size of $257 176 (IQR 62 562-770 661). Pre-clinical research received $61·1 billion (58·2%) across 70 337 (74·8%) awards and public health research received $29·5 billion (28·1%) from 19 197 (20·4%) awards. HIV/AIDS received $42·1 billion (40·1%), tuberculosis received $7·0 billion (6·7%), malaria received $5·6 billion (5·3%), and pneumonia received $3·5 billion (3·3%). Funding for Ebola virus ($1·2 billion), Zika virus ($0·3 billion), influenza ($4·4 billion), and coronavirus ($0·5 billion) was typically highest soon after a high-profile outbreak. There was a general increase in year-on-year investment in infectious disease research between 2000 and 2006, with a decline between 2007 and 2017. Funders based in the USA provided $81·6 billion (77·8%). Based on funding per 2017 disability-adjusted life years (DALYs), HIV/AIDS received the greatest relative investment ($772 per DALY), compared with tuberculosis ($156 per DALY), malaria ($125 per DALY), and pneumonia ($33 per DALY). Syphilis and scabies received the least relative investment (both $9 per DALY). We observed weak positive correlation (r=0·30) between investment and 2017 disease burden. INTERPRETATION: HIV research received the highest amount of investment relative to DALY burden. Scabies and syphilis received the lowest relative funding. Investments for high-threat pathogens (eg, Ebola virus and coronavirus) were often reactive and followed outbreaks. We found little evidence that funding is proactively guided by global burden or pandemic risk. Our findings show how research investments are allocated and how this relates to disease burden and diseases with pandemic potential. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Head MG, Brown RJ, Newell ML, et al. The allocation of USdollar;105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investments. Lancet Glob Health. 2020. PMID: 32971052. doi:10.1016/S2214-109X(20)30357-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。